| Document |
Document Title |
|
WO/2016/131333A1 |
Provided are an antioxidant complex for reducing the number of somatic cells in a livestock animal and a preparation method and application thereof. Active components of the preparation are melatonin (MT) having a concentration of 2-30 g...
|
|
WO/2016/130927A1 |
Disclosed herein are compounds of the formula: (I), wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used as antioxida...
|
|
WO/2016/127896A1 |
Disclosed is an application of an antibacterial peptide C-BF in preparation of a drug for preventing and treating stress of weaned piglets. The antibacterial peptide C-BF can improve intestinal morphology, increase the height of villi, r...
|
|
WO/2016/124605A1 |
Compositions comprising melatonin or derivatives thereof for administration to the epithelium of the lower airway to protect against lung damage due to chest irradiation and/or cytotoxic chemotherapy are provided.
|
|
WO/2016/126860A1 |
Provided are pharmaceutical dosage forms comprising (i) trientine or a pharmaceutically acceptable salt of trientine, in a (ii) sealed packaging. The sealed packaging provides a high barrier protection against air, moisture and light and...
|
|
WO/2016/125006A1 |
The invention provides an isolated, engineered, non-naturally occurring tissue protective protein or peptide (TPP) comprising a cell penetrating peptide (CPP) fused in frame with a heme oxygenase protein, or a derivative, variant, homolo...
|
|
WO/2016/119143A1 |
A lutein microcapsule preparation and preparation method, the preparation comprising the following ingredients: lutein crystals, a water-soluble emulsifier, an oil-soluble antioxidant, a wall material, a filler, a water-soluble antioxida...
|
|
WO/2016/118611A1 |
Bifunctional compounds that increase uric acid excretion and reduce uric acid production, and monofunctional compounds that either increase uric acid excretion or reduce uric acid production. Methods of using these compounds for reducing...
|
|
WO/2016/118878A1 |
A supplement includes plant-derived phosphatidylserine in a physiologically beneficial amount and at least one plant-based concentrate or extract which promotes a melatonergic benefit.
|
|
WO/2016/114860A1 |
Compounds, compositions, and methods for treatment of, or prophylaxis against, radiation exposure are disclosed.
|
|
WO/2016/115097A3 |
The present invention provides methods and compositions for specific activation of inflammatory responses in dendritic cells (DCs). 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine (PAPC) and its oxidized variant (oxPAPC) were id...
|
|
WO/2016/115097A2 |
The present invention provides methods and compositions for specific activation of inflammatory responses in dendritic cells (DCs). 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine (PAPC) and its oxidized variant (oxPAPC) were id...
|
|
WO/2016/111265A1 |
The present invention provides an antioxidant agent containing an enzymatically synthesized glycogen (ESG) or an α-amylase digest (RG) thereof, an active oxygen inhibitor, antioxidant enzyme production promotor, an antioxidant cosmetic,...
|
|
WO/2016/112381A1 |
Provided are methods of treating a disease or condition characterized by a deficiency of or a defect in an iron transporter using a small molecule. For example, the method may increase transepithelial iron transport, or it may increase i...
|
|
WO/2016/109856A1 |
This document provides dietary supplement compositions. For example, multi-supplement compositions having combinations of dietary supplement formulations useful for human or animal consumption are provided.
|
|
WO/2016/107850A1 |
The invention relates to a method for obtaining a superoxide dismutase (SOD)-concentrated protein extract having a specific activity of at least 700 UI/mg protein, said method comprising a single step of extraction from a plant selected ...
|
|
WO/2016/109002A3 |
This invention relates, in part, to methods and compositions that are useful for the treatment and/or prevention of various disorders, including radiation-related disorders, such as acute radiation syndrome.
|
|
WO/2016/103544A1 |
[Problem] To provide a novel food or drink capable of reducing alcohol concentration in blood. [Solution] A food or drink containing one or more kinds of dietary fiber components selected from the group consisting of xanthan gum, glucoma...
|
|
WO/2016/092235A1 |
The invention relates to the use of a composition comprising at least one extract of propolis, having at least one of the following properties: ‐ an antioxidant value (ORAC) greater than or equal to 500 mmol TE/100g of dry extract, ‐...
|
|
WO/2016/088816A1 |
Provided are: a compact-sized granulate of zinc acetate hydrate, in which the loss of crystallization water is suppressed during a manufacturing process by controlling the material temperature of the granulate to lower than 40°C during ...
|
|
WO/2016/088700A1 |
[Problem] To provide a method for efficient commercial manufacture of a composition containing a sweetness component from Siraitia grosvenorii, the composition containing a high concentration of mogrosides, producing a pleasant sweet qua...
|
|
WO/2016/089200A1 |
The present invention discloses an antimicrobial, antioxidant and natural preservative comprising of palm-derived carotenoid rich oil, including but not limited to, red palm oil and it's fractions that could be in the form of whole and/o...
|
|
WO/2016/087667A1 |
The present invention relates to chelates resulting from the complexation of bifunctional do2pa derivatives ligands of formula (I), wherein the substituents R1, R1', R2, R2', R3, R3', L1, L1', L2 and L2' are defined as in the claims, wit...
|
|
WO/2016/084029A1 |
The present invention relates to selected strains of bacteria belonging to the genus Lactobacillus and Bifidobacteria being able to maintaining a long-lasting homeostasis condition in a human body. Furthermore, the present invention rela...
|
|
WO/2016/082703A1 |
A preparation containing a chlorogenic acid crystal form. The crystal form is an orthorhombic crystal system, a space group is P2 12 12 1, cell parameters are as follows: a=7.7291(2)Å, b=10.9808(2)Å, c=36.5334(7)Å, α=β=γ=90.00°, Z...
|
|
WO/2016/083399A1 |
The invention relates to a pharmaceutical composition comprising alpha-ketoglutarate, optionally a glutamate dehydrogenase, and optionally a cofactor for glutamate dehydrogenase. The composition according to the invention is particularly...
|
|
WO/2016/083399A9 |
The invention relates to a pharmaceutical composition comprising alpha-ketoglutarate, optionally a glutamate dehydrogenase, and optionally a cofactor for glutamate dehydrogenase. The composition according to the invention is particularly...
|
|
WO/2016/085290A1 |
The present invention relates to an antioxidant composition containing an extracellular polysaccharide produced using Ceriporia lacerata, or a mycelium culture of Ceriporia lacerata comprising the same, or a dry powder or an extract ther...
|
|
WO/2016/081826A3 |
The invention provides methods of treatment, pharmaceutical compositions, systems and kits appropriate for first line and/or adjunct therapy with antivenom using at least one active component, in some instances at least two active compon...
|
|
WO/2016/078148A1 |
An oral solution for detoxifying alcohol. The oral solution is prepared from raw materials comprising 10-14 parts of orange peels, 4-6 parts of fermented black beans, 2-6 parts of the white stalk of scallions, 2-8 parts of Brassica rapa ...
|
|
WO/2016/078155A1 |
A kidney-replenishing traditional Chinese medicine, for which traditional Chinese medicine raw materials used in the formula thereof by weight are: 10-12 grams of Chinese parsnip, 13-15 grams of Notopterygium incisum, 5-7 grams of ramulu...
|
|
WO/2016/079553A1 |
A composition to be administered to a patient to prevent harmful effects of biological venom or chemical toxin is described. The composition includes the use of the date palm, Phoenix dactylifera fruit to be administered to a patient at ...
|
|
WO/2016/080516A1 |
The present invention provides a pharmaceutical composition containing cilnidipine or a pharmaceutically acceptable salt thereof as an active ingredient. The present invention relates to: a dynamin-related protein 1 (Drp1) polymerization...
|
|
WO/2016/075700A1 |
A herbal composition and process for preparing a detoxifying herbal extract using the stem bark of the woody liana, Dalbergia horrida for treatment of snake bite specifically Cobra (Naja naja) and Russell's viper (Daboia russelli) in mam...
|
|
WO/2016/074203A1 |
The present invention relates to a cell apoptosis inducer containing chlorine dioxide. The present invention relates to a cell apoptosis inducer kit containing the following two independent components: the first component: a chlorine dio...
|
|
WO/2016/074336A1 |
An eaglewood sachet for baths. The eaglewood sachet is prepared through the following steps: washing 34-44 parts by weight of aquilaria sinensis, 24-34 parts by weight of incense tree and 24-34 parts by weight of agilawood, drying and mi...
|
|
WO/2016/072640A1 |
The present invention relates to a detoxifying composition containing a new green extract, which is a medicinal herb, as an active ingredient. Thus, toxicities in the human body can be efficiently removed without side effects by activati...
|
|
WO/2016/072496A1 |
The present invention relates to an agent for effectively suppressing an increase in blood-acetaldehyde concentration. More specifically, the present invention relates to an alcohol metabolism promoter containing glycogen obtained from a...
|
|
WO/2016/068439A1 |
The present invention relates to a food composition and a cosmetic composition for anti-oxidation, containing, as an active ingredient, black sticky rice with giant embryos, a pulverized product thereof or an extract thereof. The composi...
|
|
WO/2016/065409A1 |
The present invention provides a fusion polypeptide comprising a first domain and a second domain, wherein the first domain comprises a polypeptide ligand which binds to a cell surface-associated antigen and the second domain comprises a...
|
|
WO/2016/063671A1 |
Provided is an ellagic acid dispersion composition that contains: an aqueous medium; solid particles which contain ellagic acid and have an average particle diameter of 200 nm or less; and at least one type of surfactant selected from am...
|
|
WO/2016/061873A1 |
Liver-protecting sober-up tea and a preparation method therefor. The tea is prepared from 7-12 g of flowers of kudzuvine, 6-8 g of dendranthemamorifolium, 8-16 g of cassia seeds, 8-10 g of mung beans, 6-12 g of glycyrrhiza uralensis fisc...
|
|
WO/2016/065360A1 |
The disclosure provides thiol-containing alkyl fatty acid and vitamin D compound formulations for intravenous, parenteral or oral administration. The compositions of the present technology have optimal controlled bioavailability and are ...
|
|
WO/2016/062125A1 |
Disclosed is an anti-fatigue preparation, health care product or food using a reduced coenzyme II as an active component. The experiments show that it can obviously prolong the weight-bearing swimming time of a mouse, increase the reserv...
|
|
WO/2016/061872A1 |
Sober-up tea, prepared from the following materials by weight: 6-8 g of chrysanthemum, 8-16 g of mulberry leaves, 6-12 g of glycyrrhiza uralensis fisch, 7-12 g of biota orientalis, 5-8 g of salvia miltiorrhiza, 3-8 g of cortex phellodend...
|
|
WO/2016/058193A1 |
A traditional Chinese medicine composition for treating suboptimal health, and a preparation method for same, the components and parts by weight of the composition for treating suboptimal health being: 25-35 parts by weight Folium artemi...
|
|
WO/2016/061264A1 |
The present disclosure relates generally to conjugates and their uses and production. More particularly, it concerns conjugates comprising an A44 or K39 gingipain adhesin peptide, or fragment thereof (e.g., an A44/K39 peptide portion) co...
|
|
WO/2016/056648A1 |
The present invention addresses the problem of providing a simple and versatile method for stabilizing 2-O-α-D-glucosyl-L-ascorbic acid in an acidic aqueous medium. The problem is solved by providing a method for stabilizing 2-O-α-D-gl...
|
|
WO/2016/052656A1 |
An autophagy inducing agent that comprises at least one member selected from a compound represented by structural formula (A), a compound represented by structural formula (B), and a compound represented by structural formula (C).
|
|
WO/2016/053953A1 |
Provided are nutritional supplement preparations and methods for enhancing the outcome of a non-invasive tissue remodeling procedure, for providing the nutritional supplement to a subject, and for preparing such supplements. A synergisti...
|
